Table 2.
Atrial fibrillation treatment strategy in rate/rhythm control and anticoagulant use at the intensive care unit and at hospital discharge for new-onset atrial fibrillation patients with AF documented in the discharge letter (n=159)
| Characteristic | |
| CHA2DS2-VASc score, median (95% CI) | 3 (3 to 4) |
| HAS-BLED score, median (95% CI) | 2 (2 to 3) |
| Rhythm/rate control, n (%) | |
| Initiated at the ICU (n=159) | |
| Amiodarone IV administered | 109 (68.6) |
| Digoxin administered | 142 (89.3) |
| Verapamil administered | 0 (0.0) |
| Beta-blocker administered | 50 (31.4) |
| Oral rate/rhythm control medication at ICU discharge* | 87 (55.1) |
| AF unresolved | 63 (39.6) |
| Hospital discharge (n=135) | |
| Rhythm/rate control medication | 87 (64.4) |
| AF unresolved | 82 (60.7) |
| Unknown rhythm | 63 (46.7) |
| Anticoagulant initiated, n (total %; % of eligible patients) | |
| Initiated at the ICU (n=159) | 43 (27.0; 25.3) |
| Therapeutic LMWH | 36 (22.6) |
| VKA | 5 (3.1) |
| NOAC | 2 (1.3) |
| Hospital discharge (n=135) | 68 (50.4; 56.3) |
| Therapeutic dose LMWH | 7 (5.2) |
| VKA | 38 (28.1) |
| NOAC | 23 (17.0) |
| One year after hospital discharge (n=99) | 36 (36.4; 38.3) |
*Oral rate/rhythm control included: amiodarone, beta-blockers, digoxin, verapamil.
AF, atrial fibrillation; ICU, intensive care unit; IV, intravenously; LMWH, low-molecular-weight heparin; NOAC, non-vitamin K antagonist oral anticoagulant; VKA, vitamin K oral antagonist.